Phase II Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
The purpose of this phase II study is to evaluate the efficacy of adaptive modification of neoadjuvant therapy in patients with resectable and borderline resectable pancreas cancer.
Study ID: PRO00030656
Trial Phase: Phase II
Trial Sponsor: Medical College of Wisconsin
Therapies Used in This Trial: Fluorouracil, Gemcitabine, Oxaliplatin, Irinotecan, Leucovorin, FOLFIRINOX, Physician's discretion on standard of care